Skip to content
Christopher T. Ritchlin, M.D., M.P.H.

Christopher T. Ritchlin, M.D., M.P.H.

Allergy, Immunology & Rheumatology

4.8 out of 5 stars
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

Psoriasis Center - Henrietta

Red Creek (Calkins Corporate Park)
400 Red Creek Drive, Suite 200
Rochester, NY 14623

About Me

Dr. Ritchlin's basic science research efforts are directed towards understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic arthritis and rheumatoid arthritis. Using a translational approach, investigators in his lab are analyzing the cell surface mol...
Dr. Ritchlin's basic science research efforts are directed towards understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic arthritis and rheumatoid arthritis. Using a translational approach, investigators in his lab are analyzing the cell surface molecules expressed by osteoclast and dendritic cell precursors with the goal to identify susceptibility and response biomarkers in patients with inflammatory arthritis. The lab is also studying the effect of anti-TNF agents on dendritic cell differentiation in RA and PsA patients. In addition, collaborative studies are underway with the lab of Dr. Eddie Schwarz to understand the mechanisms that are responsible for bone marrow edema as recorded on magnetic resonance imaging scans in inflammatory arthritis. The bulk of this work is performed in animal models but insights gained from these studies are applied to the study of human joint diseases such as psoriatic and rheumatoid arthritis.

Dr. Ritchlin is also the Director of the Clinical Immunology Research Unit where he is the principle investigator on several clinical trials testing the efficacy of anti-TNF agents and other biologic molecules in the treatment of psoriatic and rheumatoid arthritis and ankylosing spondylitis. In the Clinical Immunology Research Unit, patient oriented research is conducted on multiple levels. Investigator New Drug (IND) trials of novel agents (adalimumab, rituximab) in the treatment of PsA and AS have been completed or are about to start. Additional trials have been performed to study the effect of TNF inhibition on the frequency of osteoclast precursors and enhancing bone marrow edema in PsA. The Unit also conducts multicenter trials with novel biologic agents such as rituximab and abatacept in PsA with special attention directed towards understanding how these agents alter bone remodeling in these disorders. Additional studies underway include microanalysis assays of synovium, skin and intestinal tissues in patients with Immune Mediated Inflammatory Disorders (IMIDs) before and after TNF inhibition. Future plans include the development of ultrasound outcome measures in collaboration with Dr. Ralf Thiele and Dr. Darren Tabechian, to assess synovial, lymph node and periarticular tissue responses to different therapies in inflammatory arthritis.

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Rheumatology - American Board of Internal Medicine

Faculty Appointments

Professor (Part-Time) - Department of Medicine, Allergy/Immunology and Rheumatology (SMD)

Credentials

Residency & Fellowship

Fellowship, Rheumatology, New York University Langone Medical Center. 1986 - 1989

Residency, Internal Medicine, Mount Sinai Hospital. 1983 - 1986

Internship, Internal Medicine, Albany Medical Center Hospital. 1982 - 1983

Education

MPH | University of Rochester School of Medicine/Dentistry (USA). 2008

MD | Albany Medical College. 1982

Awards

Marquis Who's Who. 2010 - 2012

Irene Kohn Teaching Award. 2005

Irene Kohn Teaching Fellowship Award. 2004

Best Doctors in America. 2003 - 2012

Teacher of the Year Award. 1994

Henry Christian Award of Excellence in Clinical Research. 1991

Stanley Poole Award for Excellence in Internal Medicine. 1982

Alpha Omega Alpha. 1981

Research

Dr. Ritchlin's basic science research efforts are directed towards understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic arthritis and rheumatoid arthritis. Using a translational approach, investigators in his lab are analyzing the cell surface mol...
Dr. Ritchlin's basic science research efforts are directed towards understanding the mechanisms that underlie pathologic bone resorption and new bone formation in psoriatic arthritis and rheumatoid arthritis. Using a translational approach, investigators in his lab are analyzing the cell surface molecules expressed by osteoclast and dendritic cell precursors with the goal to identify susceptibility and response biomarkers in patients with inflammatory arthritis. The lab is also studying the effect of anti-TNF agents on dendritic cell differentiation in RA and PsA patients. In addition, collaborative studies are underway with the lab of Dr. Eddie Schwarz to understand the mechanisms that are responsible for bone marrow edema as recorded on magnetic resonance imaging scans in inflammatory arthritis. The bulk of this work is performed in animal models but insights gained from these studies are applied to the study of human joint diseases such as psoriatic and rheumatoid arthritis.

Dr. Ritchlin is also the Director of the Clinical Immunology Research Unit where he is the principle investigator on several clinical trials testing the efficacy of anti-TNF agents and other biologic molecules in the treatment of psoriatic and rheumatoid arthritis and ankylosing spondylitis. In the Clinical Immunology Research Unit, patient oriented research is conducted on multiple levels. Investigator New Drug (IND) trials of novel agents (adalimumab, rituximab) in the treatment of PsA and AS have been completed or are about to start. Additional trials have been performed to study the effect of TNF inhibition on the frequency of osteoclast precursors and enhancing bone marrow edema in PsA. The Unit also conducts multicenter trials with novel biologic agents such as rituximab and abatacept in PsA with special attention directed towards understanding how these agents alter bone remodeling in these disorders. Additional studies underway include microanalysis assays of synovium, skin and intestinal tissues in patients with Immune Mediated Inflammatory Disorders (IMIDs) before and after TNF inhibition. Future plans include the development of ultrasound outcome measures in collaboration with Dr. Ralf Thiele and Dr. Darren Tabechian, to assess synovial, lymph node and periarticular tissue responses to different therapies in inflammatory arthritis.

Research Lab

Pathologic Bone Resorption and New Bone Formation in Inflammatory Arthritis

Visit Research Lab Website

Patents

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: January 18, 2000

Patent #: 6,015,804

Country: United States

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: 1119362

Country: Europe

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: November 21, 2002

Patent #: 754515

Country: Australia

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: May 18, 2010

Patent #: 2,339,667

Country: Canada

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: December 08, 2003

Patent #: 509,799

Country: New Zealand

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Methods and Compositions Related to Joint Inflammation Diseases

Issue date: October 05, 2010

Patent #: 7,807,389

Country: United States

Inventors: Sally A Haas, Christopher T Ritchlin, Edward Michael Schwarz

Methods of Diagnosing Erosive Arthritis

Issue date: January 12, 2011

Patent #: 1604205

Country: Europe

Inventors: Sally A Haas, Christopher T Ritchlin, Edward Michael Schwarz

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: IT1119362

Country: Italy

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: SE119362

Country: Sweden

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: CH1119362

Country: Switzerland/Liechtenstein

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: BE1119362

Country: Belgium

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: LV1119362

Country: Latvia

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: SL1119362

Country: Slovenia

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: AL1119362

Country: Albania

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: DK1119362

Country: Denmark

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: GR1119362

Country: Greece

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: ES1119362

Country: Spain

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: RO1119362

Country: Romania

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: DE1119362

Country: Germany

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: FI1119362

Country: Finland

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: AT1119362

Country: Austria

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: FR1119362

Country: France

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: GB1119362

Country: United Kingdom

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: IE1119362

Country: Ireland

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: LU1119362

Country: Luxembourg

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: MC1119362

Country: Monaco

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: NL119362

Country: Netherlands

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: PT119362

Country: Portugal

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: LT1119362

Country: Lithuania

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 08, 2006

Patent #: MK1119362

Country: Macedonia, The Former Yugoslav Rep

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

Methods and Compositions Related to Joint Inflammation Diseases

Issue date: January 12, 2011

Patent #: FR1604205

Country: France

Inventors: Sally A Haas, Christopher T Ritchlin, Edward Michael Schwarz

Methods and Compositions Related to Joint Inflammation Diseases

Issue date: January 12, 2011

Patent #: DE1604205

Country: Germany

Inventors: Sally A Haas, Christopher T Ritchlin, Edward Michael Schwarz

Methods and Compositions Related to Joint Inflammation Diseases

Issue date: January 12, 2011

Patent #: GB1604205

Country: United Kingdom

Inventors: Sally A Haas, Christopher T Ritchlin, Edward Michael Schwarz

Method of Using Tetracycline Compounds to Enhance Interleukin-10 Production

Issue date: February 17, 2012

Patent #: 4929341

Country: Japan

Inventors: Lorne M Golub, Robert A Greenwald, Sally A Haas, Hsi-Ming Lee, Susan A Moak, Christopher T Ritchlin

DC-STAMP Antibodies

Issue date: July 25, 2017

Patent #: 2,760,330

Country: Canada

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 07, 2017

Patent #: 2424892

Country: Europe

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: April 28, 2015

Patent #: 9,018,358

Country: United States

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 05, 2018

Patent #: 9,988,448

Country: United States

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 07, 2017

Patent #: FR2424892

Country: France

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 07, 2017

Patent #: DE2424892

Country: Germany

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 07, 2017

Patent #: IT2424892

Country: Italy

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 07, 2017

Patent #: ES2424892

Country: Spain

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

DC-STAMP Antibodies

Issue date: June 07, 2017

Patent #: GB2424892

Country: United Kingdom

Inventors: Yahui Grace Chiu, Kofi A Mensah, Christopher T Ritchlin, Edward Michael Schwarz

Publications

Journal Articles

Are There Disease Endotypes in Axial Spondyloarthritis and How Would We Define Them?

Deane KD, Donlin LT, Ritchlin CT, Kuhn KA

The Journal of rheumatology.. 2024 October 24 Epub 10/24/2024.

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewé RBM, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC

Rheumatology and therapy.. 2024 August 31 Epub 08/31/2024.

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue.

Bell RD, Brendel M, Konnaris MA, Xiang J, Otero M, Fontana MA, Bai Z, , Krenitsky DM, Meednu N, Rangel-Moreno J, Scheel-Toellner D, Carr H, Nayar S, McMurray J, DiCarlo E, Anolik JH, Donlin LT, Orange DE, Kenney HM, Schwarz EM, Filer A, Ivashkiv LB, Wang F

Nature communications.. 2024 August 2915 (1):7503. Epub 08/29/2024.

Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.

Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Chakravarty SD, Rampakakis E, Shawi M, Schiopu E, Merola JF, McInnes IB, Deodhar A

Clinical rheumatology.. 2024 August 43 (8):2551-2563. Epub 06/07/2024.

Psoriatic arthritis subtypes are phenocopied in humanized mice.

Ritchlin CT, Rangel-Moreno J, Martino D, Isett B, Paine A, Bhattacharya S, Fox J, Meyer EM, Bao R, Bruno T, Tausk F, de la Luz Garcia-Hernandez M

JCI insight.. 2024 July 29 (15)Epub 07/02/2024.

Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.

Chat VS, Ellebrecht CT, Kingston P, Bell S, Gondo G, Cordoro KM, Desai SR, Duffin KC, Feldman SR, Garg A, Gelfand JM, Gladman D, Green LJ, Gudjonsson J, Han G, Hawkes JE, Kircik L, Koo J, Langley R, Lebwohl M, Michael Lewitt G, Liao W, Martin G, Orbai AM, Reddy SM, Richardson V, Ritchlin CT, Schwartzman S, Siegel EL, Van Voorhees AS, Wallace EB, Weinberg JM, Winthrop KL, Yamauchi P, Armstrong AW

Journal of the American Academy of Dermatology.. 2024 June 90 (6):1170-1181. Epub 02/07/2024.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Choi O, Krol Y, Gottlieb AB

BMC rheumatology.. 2024 May 218 (1):20. Epub 05/21/2024.

Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.

Rahman P, McInnes IB, Deodhar A, Schett G, Mease PJ, Shawi M, Cua DJ, Sherlock JP, Kollmeier AP, Xu XL, Sheng S, Ritchlin CT, McGonagle D

Clinical rheumatology.. 2024 May 43 (5):1591-1604. Epub 03/12/2024.

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.

Coates LC, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Orbai AM, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Merola JF

RMD open.. 2024 February 2210 (1)Epub 02/22/2024.

IL-23 induces CLEC5A IL-17A neutrophils and elicit skin inflammation associated with psoriatic arthritis.

Furuya H, Nguyen CT, Chan T, Marusina AI, Merleev AA, Garcia-Hernandez ML, Hsieh SL, Tsokos GC, Ritchlin CT, Tagkopoulos I, Maverakis E, Adamopoulos IE

Journal of autoimmunity.. 2024 February 143 :103167. Epub 02/01/2024.

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.

Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, Fourie A, Fakharzadeh S, Sherlock JP, Yang YW, Cua DJ, McInnes IB

Frontiers in immunology.. 2024 15 :1331217. Epub 04/15/2024.

High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy.

Kenney HM, Chen KL, Schnur L, Fox JI, Wood RW, Xing L, Ritchlin CT, Rahimi H, Schwarz EM, Awad HA

PloS one.. 2024 19 (7):e0305623. Epub 07/05/2024.

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.

Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landewé RB

Annals of the rheumatic diseases.. 2023 November 82 (11):1404-1414. Epub 09/11/2023.

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.

Siebert S, Sweet KM, Ritchlin CT, Hsia EC, Kollmeier AP, Xu XL, Seridi L, Song Q, Gao S, Chen W, Miron M

ACR open rheumatology.. 2023 September 5 (9):490-498. Epub 08/08/2023.

Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands.

Kenney HM, Dieudonne G, Yee S, Maki JH, Wood RW, Schwarz EM, Ritchlin CT, Rahimi H

Lymphatic research and biology.. 2023 August 21 (4):388-395. Epub 02/20/2023.

Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Tumor Necrosis Factor Inhibitor.

Leung YY, Kavanaugh A, Ritchlin CT

Arthritis & rheumatology.. 2023 August 75 (8):1312-1324. Epub 05/24/2023.

The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?

Kenney HM, Peng Y, de Mesy Bentley KL, Xing L, Ritchlin CT, Schwarz EM

Current rheumatology reviews.. 2023 June 519 (3):246-259. Epub 1900 01 01.

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.

McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Chakravarty SD, Kollmeier AP, Xu XL, Sheng S, Xu S, Ritchlin CT, Rahman P, Mease PJ

ACR open rheumatology.. 2023 April 5 (4):227-240. Epub 03/07/2023.

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.

Ritchlin CT, Deodhar A, Boehncke WH, Soriano ER, Kollmeier AP, Xu XL, Zazzetti F, Shawi M, Jiang Y, Sheng S, Helliwell PS

ACR open rheumatology.. 2023 March 5 (3):149-164. Epub 02/10/2023.

Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice.

Kenney HM, Wood RW, Ramirez G, Bell RD, Chen KL, Schnur L, Rahimi H, Korman BD, Xing L, Ritchlin CT, Schwarz EM, Cole CL

Arthritis research & therapy.. 2023 February 225 (1):17. Epub 02/02/2023.

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.

Coates LC, Ritchlin CT, Gossec L, Helliwell PS, Rahman P, Kollmeier AP, Xu XL, Shawi M, Karyekar CS, Contré C, Noël W, Sheng S, Wang Y, Xu S, Mease PJ

Rheumatology.. 2023 February 162 (2):606-616. Epub 1900 01 01.

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.

Ritchlin CT, Coates LC, Mease PJ, van der Heijde D, Song J, Jiang Y, Shawi M, Kollmeier AP, Rahman P

Trials.. 2023 January 1024 (1):22. Epub 01/10/2023.

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).

McInnes IB, Asahina A, Coates LC, Landewé R, Merola JF, Ritchlin CT, Tanaka Y, Gossec L, Gottlieb AB, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Mease PJ

Lancet.. 2023 January 7401 (10370):25-37. Epub 12/06/2022.

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-? inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).

Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC

Lancet.. 2023 January 7401 (10370):38-48. Epub 12/06/2022.

Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation.

Bawany F, Ryan Wolff J, Ritchlin CT, Tausk F

Clinical, cosmetic and investigational dermatology.. 2023 16 :1175-1180. Epub 05/02/2023.

Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.

Kenney HM, Rangel-Moreno J, Peng Y, Chen KL, Bruno J, Embong A, Pritchett E, Fox JI, Becerril-Villanueva E, Gamboa-Domínguez A, Quataert S, Muthukrishnan G, Wood RW, Korman BD, Anolik JH, Xing L, Ritchlin CT, Schwarz EM, Wu CL

Frontiers in immunology.. 2023 14 :1237498. Epub 08/25/2023.

Distinct mast cell subpopulations within and around lymphatic vessels regulate lymph flow and progression of inflammatory-erosive arthritis in TNF-transgenic mice.

Peng Y, Kenney HM, de Mesy Bentley KL, Xing L, Ritchlin CT, Schwarz EM

Frontiers in immunology.. 2023 14 :1275871. Epub 12/14/2023.

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.

Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, Gossec L, Assudani D, Bajracharya R, Coarse J, Ink B, Ritchlin CT

Arthritis & rheumatology.. 2022 December 74 (12):1959-1970. Epub 11/18/2022.

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.

Orbai AM, Coates LC, Deodhar A, Helliwell PS, Ritchlin CT, Leibowitz E, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Jiang Y, Liu Y, Han C

The patient.. 2022 November 15 (6):657-668. Epub 06/30/2022.

Small Molecule Inhibitors of Nuclear Export and the Amelioration of Lupus by Modulation of Plasma Cell Generation and Survival.

Rangel-Moreno J, Garcia-Hernandez ML, Owen T, Barnard J, Becerril-Villanueva E, Kashyap T, Argueta C, Gamboa-Dominguez A, Tamir S, Landesman Y, Goldman BI, Ritchlin CT, Anolik JH

Arthritis & rheumatology.. 2022 August 74 (8):1363-1375. Epub 06/28/2022.

Persistent popliteal lymphatic muscle cell coverage defects despite amelioration of arthritis and recovery of popliteal lymphatic vessel function in TNF-Tg mice following anti-TNF therapy.

Kenney HM, Peng Y, Bell RD, Wood RW, Xing L, Ritchlin CT, Schwarz EM

Scientific reports.. 2022 July 2612 (1):12751. Epub 07/26/2022.

Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.

Stober C, McInnes IB, Raychaudhuri S, Mease PJ, Pennington SR, Scher JU, Chandran V, Armstrong AW, de Wit M, Cauli A, Jadon DR, Löve TJ, Ogdie A, O'Sullivan D, van Mens LJJ, Ritchlin CT, FitzGerald O

The Journal of rheumatology.. 2022 June 49 (6 Suppl 1):57-63. Epub 04/01/2022.

Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.

Kenney HM, Wu CL, Loiselle AE, Xing L, Ritchlin CT, Schwarz EM

Arthritis research & therapy.. 2022 March 724 (1):64. Epub 03/07/2022.

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.

Ritchlin CT, Mease PJ, Boehncke WH, Tesser J, Schiopu E, Chakravarty SD, Kollmeier AP, Xu XL, Shawi M, Jiang Y, Sheng S, Wang Y, Xu S, Merola JF, McInnes IB, Deodhar A

RMD open.. 2022 March 8 (1)Epub 1900 01 01.

Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.

Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, Carballido JM, Häusermann P, Calonder C, Vogel B, Rondeau JM, Bruin G

Pharmacology & therapeutics.. 2022 January 229 :107925. Epub 06/23/2021.

Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.

Gondo GC, Noe MH, Bell SJ, Ritchlin CT

Journal of psoriasis and psoriatic arthritis.. 2022 January 7 (1):17-23. Epub 12/10/2021.

Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritis.

Garcia-Hernandez ML, Rangel-Moreno J, Garcia-Castaneda M, Kenney HM, Paine A, Thullen M, Anandarajah AP, Schwarz EM, Dirksen RT, Ritchlin CT

Frontiers in immunology.. 2022 13 :1026574. Epub 11/07/2022.

Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB

The Journal of rheumatology.. 2021 December 48 (12):1815-1823. Epub 05/01/2021.

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.

McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Ritchlin CT, Rahman P, Mease PJ

Rheumatology.. 2021 November 360 (11):5337-5350. Epub 1900 01 01.

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.

Pournara E, Kormaksson M, Nash P, Ritchlin CT, Kirkham BW, Ligozio G, Pricop L, Ogdie A, Coates LC, Schett G, McInnes IB

RMD open.. 2021 November 7 (3)Epub 1900 01 01.

Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.

Stober C, Jadon DR, Armstrong AW, Chandran V, de Wit M, Helliwell PS, Mease PJ, Ogdie A, O'Sullivan D, Pennington SR, Löve T, Cauli A, van Mens L, Waxman R, Scher JU, Barton A, Ritchlin CT, FitzGerald O

The Journal of rheumatology. Supplement.. 2021 June 97 :4-9. Epub 1900 01 01.

Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.

Ogdie A, Ritchlin CT

The Journal of rheumatology. Supplement.. 2021 June 97 :17-18. Epub 1900 01 01.

GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.

Ritchlin CT, Armstrong A, Johnsson H, Mulder MLM

The Journal of rheumatology. Supplement.. 2021 June 97 :19-23. Epub 1900 01 01.

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT

Journal of the American Academy of Dermatology.. 2021 May 84 (5):1254-1268. Epub 01/07/2021.

Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.

Ogdie A, Ritchlin CT

The Journal of rheumatology.. 2021 February 15 Epub 02/15/2021.

Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.

Stober C, Jadon DR, Armstrong AW, Chandran V, de Wit M, Helliwell PS, Mease P, Ogdie A, O'Sullivan D, Pennington SR, Löve T, Cauli A, van Mens L, Waxman R, Scher JU, Barton A, Ritchlin CT, FitzGerald O

The Journal of rheumatology.. 2021 February 15 Epub 02/15/2021.

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF? inhibitor-experienced.

Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, Chakravarty SD, Zazzetti F, Subramanian RA, Xu XL, Zuraw QC, Sheng S, Jiang Y, Agarwal P, Zhou B, Zhuang Y, Shawi M, Karyekar CS, Deodhar A

RMD open.. 2021 February 7 (1)Epub 1900 01 01.

Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis.

Scallan JP, Bouta EM, Rahimi H, Kenney HM, Ritchlin CT, Davis MJ, Schwarz EM

Frontiers in physiology.. 2021 12 :745096. Epub 09/27/2021.

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT

Journal of the American Academy of Dermatology.. 2020 December 83 (6):1704-1716. Epub 09/04/2020.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT

Arthritis care & research.. 2020 November 72 (11):1579-1588. Epub 1900 01 01.

Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors.

Kenney HM, Bell RD, Masters EA, Xing L, Ritchlin CT, Schwarz EM

Scientific reports.. 2020 October 2210 (1):18088. Epub 10/22/2020.

Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Bell RD, White RJ, Garcia-Hernandez ML, Wu E, Rahimi H, Marangoni RG, Slattery P, Duemmel S, Nuzzo M, Huertas N, Yee M, O'Reilly MA, Morrell C, Ritchlin CT, Schwarz EM, Korman BD

Arthritis & rheumatology.. 2020 October 72 (10):1759-1770. Epub 08/20/2020.

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.

Ritchlin CT, Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell P, Young P, Wang C, Wu J, Romero AB, Woolcott J, Stockert L

ACR open rheumatology.. 2020 October 2 (10):543-554. Epub 09/10/2020.

Altered Lymphatic Vessel Anatomy and Markedly Diminished Lymph Clearance in Affected Hands of Patients With Active Rheumatoid Arthritis.

Bell RD, Rahimi H, Kenney HM, Lieberman AA, Wood RW, Schwarz EM, Ritchlin CT

Arthritis & rheumatology.. 2020 September 72 (9):1447-1455. Epub 1900 01 01.

GRAPPA Trainees Symposium 2019: A Report from the GRAPPA 2019 Annual Meeting.

Hughes CD, van Mens LJJ, Boehncke WH, Ritchlin CT

The Journal of rheumatology. Supplement.. 2020 June 96 :4-10. Epub 1900 01 01.

Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis.

Ritchlin CT, Pennington SR, Reynolds NJ, FitzGerald O

The Journal of rheumatology. Supplement.. 2020 June 96 :19-24. Epub 1900 01 01.

Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting.

Waxman R, Stober C, Jadon DR, Orbai AM, Chandran V, Ogdie A, Pennington SR, de Wit M, O'Sullivan D, Mease PJ, Armstrong AW, Callis Duffin K, Helliwell PS, van Mens LJJ, Ritchlin CT, FitzGerald O

The Journal of rheumatology. Supplement.. 2020 June 96 :25-30. Epub 1900 01 01.

GRAPPA 2019 Project Report.

Goel N, Coates LC, De Marco G, Eder L, FitzGerald O, Helliwell PS, Leung YY, Maksymowych WP, Mease PJ, Østergaard M, O'Sullivan D, Poddubnyy D, Ritchlin CT, Gladman DD

The Journal of rheumatology. Supplement.. 2020 June 96 :53-57. Epub 1900 01 01.

Evan Calkins, MD, 1920-2020.

Ritchlin CT

Arthritis & rheumatology.. 2020 May 6 Epub 05/06/2020.

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF? inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.

Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT

Lancet.. 2020 April 4395 (10230):1115-1125. Epub 03/13/2020.

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.

McInnes IB, Ink B, Coarse J, Bedford-Rice K, Assudani D, Gottlieb AB, Warren RB, Scher JU, Schett G, Merola JF, Kavanaugh A, Ritchlin CT

Lancet.. 2020 February 8395 (10222):427-440. Epub 1900 01 01.

TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21/CD23 B Cell Follicles Is Prevented with Anti-TNF Therapy.

Wu EK, Henkes ZI, McGowan B, Bell RD, Velez MJ, Livingstone AM, Ritchlin CT, Schwarz EM, Rahimi H

The Journal of immunology : official journal of the American Association of Immunologists.. 2019 December 1203 (11):2837-2849. Epub 10/28/2019.

iNOS dependent and independent phases of lymph node expansion in mice with TNF-induced inflammatory-erosive arthritis.

Bell RD, Slattery PN, Wu EK, Xing L, Ritchlin CT, Schwarz EM

Arthritis research & therapy.. 2019 November 1421 (1):240. Epub 11/14/2019.

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin CT, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A,

The Journal of rheumatology.. 2019 November 46 (11):1458-1461. Epub 04/01/2019.

Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid Arthritis.

Bell DR, Wu E, Rudmann C, Forney M, Kaiser C, Wood R, Chakkalakal J, Paris N, Klose A, Xiao GQ, Rangel-Moreno J, Garcia-Hernandez M, Ritchlin C, Schwarz E, Rahimi H

Arthritis & rheumatology.. 2019 September 71 (9):1512-1523. Epub 07/22/2019.

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.

Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB

Arthritis & rheumatology.. 2019 July 71 (7):1112-1124. Epub 05/28/2019.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC

Rheumatology.. 2019 June 158 (6):1025-1033. Epub 1900 01 01.

GRAPPA Trainees Symposium 2018: A Report from the GRAPPA 2018 Annual Meeting.

Ford AR, Mascia E, Boehncke WH, Ritchlin CT

The Journal of rheumatology. Supplement.. 2019 June 95 :4-10. Epub 1900 01 01.

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, O'Sullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O

The Journal of rheumatology. Supplement.. 2019 June 95 :11-19. Epub 1900 01 01.

GRAPPA 2018 Project Report.

Goel N, FitzGerald O, Gladman DD, Helliwell PS, Kavanaugh A, Maksymowych WP, Mease PJ, Ritchlin CT, Coates LC

The Journal of rheumatology. Supplement.. 2019 June 95 :54-57. Epub 1900 01 01.

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.

Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, Kanik KS, Hendrikx T, Berstein G, Hodge J, Telliez JB

Rheumatology.. 2019 February 158 (2):197-205. Epub 1900 01 01.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J

Arthritis & rheumatology.. 2019 January 71 (1):5-32. Epub 11/30/2018.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J

Arthritis care & research.. 2019 January 71 (1):2-29. Epub 11/30/2018.

Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.

Wu EK, Ambrosini RD, Kottmann RM, Ritchlin CT, Schwarz EM, Rahimi H

Current rheumatology reviews.. 2019 15 (4):277-289. Epub 1900 01 01.

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.

Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, Srivastava B, Langholff W, Gottlieb AB

BMC rheumatology.. 2019 3 :52. Epub 11/28/2019.

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD

The Journal of rheumatology.. 2018 October 45 (10):1389-1396. Epub 07/01/2018.

Thy1 is a positive regulator of osteoblast differentiation and modulates bone homeostasis in obese mice.

Paine A, Woeller CF, Zhang H, de la Luz Garcia-Hernandez M, Huertas N, Xing L, Phipps RP, Ritchlin CT

FASEB journal : official publication of the Federation of American Societies for Experimental Biology.. 2018 June 32 (6):3174-3183. Epub 01/17/2018.

GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting.

Furer V, Manasson J, Boehncke WH, Ritchlin CT

The Journal of rheumatology. Supplement.. 2018 June 94 :4-10. Epub 1900 01 01.

GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC

The Journal of rheumatology. Supplement.. 2018 June 94 :48-51. Epub 1900 01 01.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT

The Journal of rheumatology. Supplement.. 2018 June 94 :54-61. Epub 1900 01 01.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Nash P, Mease PJ, McInnes IB, Rahman P, Ritchlin CT, Blanco R, Dokoupilova E, Andersson M, Kajekar R, Mpofu S, Pricop L,

Arthritis research & therapy.. 2018 March 1520 (1):47. Epub 03/15/2018.

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.

Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD

The Journal of rheumatology.. 2018 March 45 (3):378-384. Epub 02/01/2018.

Chronic social stress Ameliorates psoriasiform dermatitis through upregulation of the Hypothalamic-Pituitary-Adrenal axis.

Vegas O, Poligone B, Blackcloud P, Gilmore ES, VanBuskirk J, Ritchlin CT, Pentland AP, Walter SA, Nousari Y, Tausk F

Brain, behavior, and immunity.. 2018 February 68 :238-247. Epub 11/07/2017.

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Bouta EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham CO, Ritchlin CT, Schwarz EM

Nature reviews. Rheumatology.. 2018 February 14 (2):94-106. Epub 01/11/2018.

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD

RMD open.. 2018 4 (1):e000638. Epub 04/25/2018.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S

Rheumatology.. 2017 November 156 (11):1993-2003. Epub 1900 01 01.

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD

Arthritis care & research.. 2017 November 69 (11):1692-1699. Epub 1900 01 01.

Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca /NFATc1 Axis.

Chiu YH, Schwarz E, Li D, Xu Y, Sheu TR, Li J, Bentley KL, Feng C, Wang B, Wang JC, Albertorio-Saez L, Wood R, Kim M, Wang W, Ritchlin CT

Journal of cellular physiology.. 2017 September 232 (9):2538-2549. Epub 04/12/2017.

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD

The Journal of rheumatology.. 2017 August 44 (8):1151-1158. Epub 06/15/2017.

Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis.

Sun W, Zhang H, Wang H, Chiu YG, Ritchlin CT, Kiernan A, Boyce BF, Xing L

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.. 2017 July 32 (7):1469-1480. Epub 04/10/2017.

Brief Report: Treatment of Tumor Necrosis Factor-Transgenic Mice With Anti-Tumor Necrosis Factor Restores Lymphatic Contractions, Repairs Lymphatic Vessels, and May Increase Monocyte/Macrophage Egress.

Bouta EM, Kuzin I, de Mesy Bentley K, Wood RW, Rahimi H, Ji RC, Ritchlin CT, Bottaro A, Xing L, Schwarz EM

Arthritis & rheumatology.. 2017 June 69 (6):1187-1193. Epub 04/04/2017.

Psoriatic Arthritis.

Ritchlin CT, Colbert RA, Gladman DD

The New England journal of medicine.. 2017 May 25376 (21):2095-6. Epub 1900 01 01.

GRAPPA Trainees Symposium 2016: A Report from the GRAPPA 2016 Annual Meeting.

Polachek A, Stober CB, Gudbjornsson B, Ritchlin CT

The Journal of rheumatology.. 2017 May 44 (5):661-667. Epub 1900 01 01.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS

The Journal of rheumatology.. 2017 May 44 (5):668-673. Epub 1900 01 01.

Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting.

Krueger JG, Kirkham B, Ritchlin CT

The Journal of rheumatology.. 2017 May 44 (5):679-683. Epub 1900 01 01.

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

Coates LC, Chandran V, Ogdie A, O'Sullivan D, Brooke M, Steinkoenig I, Mease PJ, Ritchlin CT, Kavanaugh A

The Journal of rheumatology.. 2017 May 44 (5):684-685. Epub 1900 01 01.

Psoriatic Arthritis.

Ritchlin CT, Colbert RA, Gladman DD

The New England journal of medicine.. 2017 March 9376 (10):957-970. Epub 1900 01 01.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD,

Annals of the rheumatic diseases.. 2017 January 76 (1):79-87. Epub 08/23/2016.

Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.

Chiu YG, Ritchlin CT

Expert opinion on biological therapy.. 2017 January 17 (1):119-128. Epub 11/30/2016.

MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis.

Yoo SA, Leng L, Kim BJ, Du X, Tilstam PV, Kim KH, Kong JS, Yoon HJ, Liu A, Wang T, Song Y, Sauler M, Bernhagen J, Ritchlin CT, Lee P, Cho CS, Kim WU, Bucala R

Proceedings of the National Academy of Sciences of the United States of America.. 2016 December 6113 (49):E7917-E7926. Epub 11/21/2016.

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS

Nature reviews. Rheumatology.. 2016 December 12 (12):743-750. Epub 11/10/2016.

DC-STAMP: A Key Regulator in Osteoclast Differentiation.

Chiu YG, Ritchlin CT

Journal of cellular physiology.. 2016 November 231 (11):2402-7. Epub 06/14/2016.

Lymphatic imaging to assess rheumatoid flare: mechanistic insights and biomarker potential.

Rahimi H, Bell R, Bouta EM, Wood RW, Xing L, Ritchlin CT, Schwarz EM

Arthritis research & therapy.. 2016 September 118 :194. Epub 09/01/2016.

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.

Thurmond RL, Greenspan A, Radziszewski W, Xu XL, Miao Y, Chen B, Ge T, Zhou B, Baker DG, Pavlova D, Ritchlin CT, Tanaka Y, Takeuchi T, Smolen JS

The Journal of rheumatology.. 2016 September 43 (9):1637-42. Epub 07/15/2016.

Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Paine A, Ritchlin CT

Current opinion in rheumatology.. 2016 July 28 (4):359-67. Epub 1900 01 01.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta Felquer M, Armstrong AW, Bautista Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Elaine Husni M, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT

Arthritis & rheumatology.. 2016 May 68 (5):1060-71. Epub 03/23/2016.

New therapies for psoriasis and psoriatic arthritis.

Ritchlin CT, Krueger JG

Current opinion in rheumatology.. 2016 May 28 (3):204-10. Epub 1900 01 01.

GRAPPA Trainees Symposium 2015: A Report from the GRAPPA 2015 Annual Meeting.

Milliken M, Generali E, Marin J, Ritchlin CT

The Journal of rheumatology.. 2016 May 43 (5):952-8. Epub 1900 01 01.

Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study.

Rahimi H, Dieudonne G, Kheyfits V, Bouta EM, Wood RW, Barrett R, Moorehead S, Schwarz EM, Ritchlin CT

Clinical medicine insights. Arthritis and musculoskeletal disorders. 2016 9 :203-208. Epub 12/14/2016.

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT

American journal of human genetics.. 2015 December 397 (6):816-36. Epub 11/28/2015.

Etiology and Pathogenesis of Psoriatic Arthritis.

Barnas JL, Ritchlin CT

Rheumatic diseases clinics of North America.. 2015 November 41 (4):643-63. Epub 08/30/2015.

Psoriatic Arthritis.

Ritchlin CT

Rheumatic diseases clinics of North America.. 2015 November 41 (4):xiii-xiv. Epub 1900 01 01.

An Integrative Approach to Biomarker Development in Psoriatic Arthritis.

Ritchlin CT

The Journal of rheumatology. Supplement.. 2015 November 93 :43-7. Epub 1900 01 01.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S,

Lancet.. 2015 September 19386 (9999):1137-46. Epub 06/28/2015.

Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan.

Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, Deshpande GA, Ritchlin CT, Tanaka A, Higashiyama M, Matsui K, Tsuji S

The Journal of rheumatology.. 2015 August 42 (8):1439-42. Epub 06/15/2015.

Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis.

Thom N, Ritchlin CT, Zhang X, Reveille J, Weisman MH

Arthritis care & research.. 2015 May 67 (6):829-35. Epub 1900 01 01.

Validation of power Doppler versus contrast-enhanced magnetic resonance imaging quantification of joint inflammation in murine inflammatory arthritis.

Bouta EM, Banik PD, Wood RW, Rahimi H, Ritchlin CT, Thiele RG, Schwarz EM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.. 2015 April 30 (4):690-4. Epub 1900 01 01.

Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis.

Siegel EL, Orbai AM, Ritchlin CT

Current opinion in rheumatology.. 2015 March 27 (2):111-7. Epub 1900 01 01.

The role of the lymphatic system in inflammatory-erosive arthritis.

Bouta EM, Li J, Ju Y, Brown EB, Ritchlin CT, Xing L, Schwarz EM

Seminars in cell & developmental biology.. 2015 February 38 :90-7. Epub 01/15/2015.

Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies.

Anandarajah A, Thiele R, Giampoli E, Monu J, Seo GS, Feng C, Ritchlin C

The Journal of rheumatology.. 2014 November 41 (11):2153-60. Epub 10/01/2014.

Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA.

Coates LC, Kavanaugh A, Ritchlin CT,

The Journal of rheumatology.. 2014 November 41 (11):2273-6. Epub 1900 01 01.

Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis.

Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, Luime JJ, Elkayam O, Neerinckx B, Urbancek S, de Vlam K, Ritchlin CT,

The Journal of rheumatology.. 2014 November 41 (11):2290-4. Epub 1900 01 01.

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A

The New England journal of medicine.. 2014 June 12370 (24):2295-306. Epub 1900 01 01.

GRAPPA Trainees Symposium 2013: a report from the GRAPPA 2013 Annual Meeting.

Szentpetery A, Johnson MA, Ritchlin CT

The Journal of rheumatology.. 2014 June 41 (6):1200-5. Epub 1900 01 01.

Psoriatic enthesitis: an update from the GRAPPA 2013 Annual Meeting.

Ritchlin CT

The Journal of rheumatology.. 2014 June 41 (6):1220-3. Epub 1900 01 01.

GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting.

Coates LC, Ritchlin CT, Kavanaugh AF

The Journal of rheumatology.. 2014 June 41 (6):1237-9. Epub 1900 01 01.

Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.

Weitz JE, Ritchlin CT

Expert opinion on biological therapy.. 2014 April 14 (4):515-26. Epub 02/20/2014.

In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice.

Bouta EM, Wood RW, Brown EB, Rahimi H, Ritchlin CT, Schwarz EM

The Journal of physiology.. 2014 March 15592 (6):1213-23. Epub 01/13/2014.

A127: validating popliteal lymph node phenotype and bin expansion as biomarkers of rheumatoid arthritis knee flare in clinical pilot studies.

Rahimi H, Wood R, Kuzin I, Tyler W, Dieudonne G, Kates S, Ritchlin CT, Schwarz EM

Arthritis & rheumatology.. 2014 March 66 Suppl 3 :S166-7. Epub 1900 01 01.

Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody.

Kobie JJ, Treanor JJ, Ritchlin CT

Immunological investigations.. 2014 43 (6):606-15. Epub 1900 01 01.

Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy.

Rosenberg A, Fan H, Chiu YG, Bolce R, Tabechian D, Barrett R, Moorehead S, Baribaud F, Liu H, Peffer N, Shealy D, Schwarz EM, Ritchlin CT

PloS one.. 2014 9 (10):e110657. Epub 10/21/2014.

Proceedings of the 5th annual perspectives in rheumatic diseases.

Furst DE, Mandell B, Calabrese LH, Cather JC, Clauw DJ, Deodhar A, Kremer JM, Lewiecki EM, McMahon M, Ritchlin CT

Seminars in arthritis and rheumatism.. 2013 December 43 (3):416-9. Epub 1900 01 01.

Mechanistic insights from animal models of psoriasis and psoriatic arthritis.

Weitz JE, Ritchlin CT

Current rheumatology reports.. 2013 November 15 (11):377. Epub 1900 01 01.

Troponin T3 expression in skeletal and smooth muscle is required for growth and postnatal survival: characterization of Tnnt3(tm2a(KOMP)Wtsi) mice.

Ju Y, Li J, Xie C, Ritchlin CT, Xing L, Hilton MJ, Schwarz EM

Genesis : the journal of genetics and development.. 2013 September 51 (9):667-75. Epub 07/09/2013.

GRAPPA Trainees Symposium 2012: a report from the GRAPPA 2012 annual meeting.

Garg N, Touma Z, Ritchlin CT

The Journal of rheumatology.. 2013 August 40 (8):1413-8. Epub 1900 01 01.

Characterization of DC-STAMP+ Cells in Human Bone Marrow.

Chiu YG, Ritchlin CT

Journal of bone marrow research.. 2013 July 191 Epub 1900 01 01.

Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow.

Li J, Ju Y, Bouta EM, Xing L, Wood RW, Kuzin I, Bottaro A, Ritchlin CT, Schwarz EM

Arthritis and rheumatism.. 2013 January 65 (1):130-8. Epub 1900 01 01.

GRAPPA Trainees Symposium 2011: a report from the GRAPPA 2011 annual meeting.

Ash Z, Ritchlin CT

The Journal of rheumatology.. 2012 November 39 (11):2184-8. Epub 1900 01 01.

Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting.

Fitzgerald O, Ritchlin CT, Mease PJ

The Journal of rheumatology.. 2012 November 39 (11):2189-92. Epub 1900 01 01.

Altered bone biology in psoriatic arthritis.

Rahimi H, Ritchlin CT

Current rheumatology reports.. 2012 August 14 (4):349-57. Epub 1900 01 01.

GRAPPA Trainees Symposium 2010: a report from the GRAPPA 2010 annual meeting.

Ritchlin CT

The Journal of rheumatology.. 2012 February 39 (2):394-7. Epub 1900 01 01.

Strategies for biomarker development in psoriatic disease: a report from the GRAPPA 2010 annual meeting.

Ritchlin CT

The Journal of rheumatology.. 2012 February 39 (2):423-6. Epub 1900 01 01.

The path forward to biomarker discovery in psoriatic disease: a report from the GRAPPA 2010 annual meeting.

Gladman DD, Ritchlin CT, Fitzgerald O

The Journal of rheumatology.. 2012 February 39 (2):434-6. Epub 1900 01 01.

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P,

Annals of the rheumatic diseases.. 2012 January 71 (1):4-12. Epub 09/27/2011.

Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).

Chiu YH, Mensah KA, Schwarz EM, Ju Y, Takahata M, Feng C, McMahon LA, Hicks DG, Panepento B, Keng PC, Ritchlin CT

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.. 2012 January 27 (1):79-92. Epub 1900 01 01.

Consensus guidelines for the management of plaque psoriasis.

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF

Archives of dermatology.. 2012 January 148 (1):95-102. Epub 1900 01 01.

Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis.

Chiu YH, Ritchlin CT

Psoriasis forum. 2012 18 (2):2-10. Epub 1900 01 01.

Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.

Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Mack M, Kremer J

The Journal of rheumatology.. 2011 December 38 (12):2572-80. Epub 11/15/2011.

Measuring intranodal pressure and lymph viscosity to elucidate mechanisms of arthritic flare and therapeutic outcomes.

Bouta EM, Wood RW, Perry SW, Brown EB, Ritchlin CT, Xing L, Schwarz EM

Annals of the New York Academy of Sciences.. 2011 December 1240 :47-52. Epub 1900 01 01.

CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice.

Li J, Zhou Q, Wood R, Kuzin I, Bottaro A, Ritchlin C, Xing L, Schwarz E

Arthritis research & therapy.. 2011 August 3113 (4):R138. Epub 08/31/2011.

Association between focal erosions and generalised bone loss in psoriatic arthritis.

Anandarajah AP, El-Taha M, Peng C, Reed G, Greenberg JD, Ritchlin CT

Annals of the rheumatic diseases.. 2011 July 70 (7):1345-7. Epub 02/16/2011.

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D

Arthritis and rheumatism.. 2011 April 63 (4):939-48. Epub 1900 01 01.

GRAPPA Trainees Symposium 2009: a report from the GRAPPA 2009 annual meeting.

Coates LC, Ritchlin CT

The Journal of rheumatology.. 2011 March 38 (3):526-9. Epub 1900 01 01.

Summary of the International Federation of Psoriasis Associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting.

Coates LC, Jonckheere CL, Molin S, Mease PJ, Ritchlin CT

The Journal of rheumatology.. 2011 March 38 (3):530-9. Epub 1900 01 01.

High-resolution interleaved water-fat MR imaging of finger joints with chemical-shift elimination.

Kwok WE, You Z, Seo G, Lerner A, Totterman S, Ritchlin C, Monu J

Journal of magnetic resonance imaging : JMRI.. 2011 January 33 (1):245-51. Epub 1900 01 01.

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I

Arthritis research & therapy.. 2011 13 (6):R209. Epub 12/16/2011.

Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry.

Reddy SM, Anandarajah AP, Fisher MC, Mease PJ, Greenberg JD, Kremer JM, Reed G, Chen R, Messing S, Kaukeinen K, Ritchlin CT

The Journal of rheumatology.. 2010 December 37 (12):2566-72. Epub 09/15/2010.

Therapeutic considerations in spondyloarthritis patients who fail tumour necrosis factor antagonists.

Ritchlin CT

Best practice & research. Clinical rheumatology.. 2010 October 24 (5):683-92. Epub 1900 01 01.

RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens.

Mensah KA, Ritchlin CT, Schwarz EM

Journal of cellular physiology.. 2010 April 223 (1):76-83. Epub 1900 01 01.

Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis.

Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM

Arthritis and rheumatism.. 2010 April 62 (4):1127-37. Epub 1900 01 01.

Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008.

Coates LC, McGonagle DM, Hodgson R, Gisondi P, Kavanaugh AF, Qureshi AA, Fitzgerald O, Mease PJ, Garg A, Rosen CF, Ridley D, Gladman DD, Krueger GG, Ritchlin CT, Helliwell PS

The Journal of rheumatology.. 2010 February 37 (2):448-52. Epub 1900 01 01.

Composite measures in psoriatic arthritis: GRAPPA 2008.

Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A

The Journal of rheumatology.. 2010 February 37 (2):453-61. Epub 1900 01 01.

Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008.

Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, Gladman DD, Krueger GG, Kavanaugh AF, Fitzgerald O

The Journal of rheumatology.. 2010 February 37 (2):462-7. Epub 1900 01 01.

Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging.

Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT

Annals of the rheumatic diseases.. 2010 January 69 (1):206-9. Epub 1900 01 01.

High-resolution uniform MR imaging of finger joints using a dedicated RF coil at 3T.

Kwok WE, You Z, Monu J, Seo G, Ritchlin C

Journal of magnetic resonance imaging : JMRI.. 2010 January 31 (1):240-7. Epub 1900 01 01.

The role of bone marrow edema and lymphangiogenesis in inflammatory-erosive arthritis.

Schwarz EM, Proulx ST, Ritchlin CT, Boyce BF, Xing L

Advances in experimental medicine and biology.. 2010 658 :1-10. Epub 1900 01 01.

CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis.

Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, Ritchlin CT

Arthritis research & therapy.. 2010 12 (1):R14. Epub 01/26/2010.

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.

Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH

Arthritis research & therapy.. 2010 12 (3):R113. Epub 06/10/2010.

The diagnosis and treatment of early psoriatic arthritis.

Anandarajah AP, Ritchlin CT,

Nature reviews. Rheumatology.. 2009 November 5 (11):634-41. Epub 10/06/2009.

Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis.

Guo R, Zhou Q, Proulx ST, Wood R, Ji RC, Ritchlin CT, Pytowski B, Zhu Z, Wang YJ, Schwarz EM, Xing L

Arthritis and rheumatism.. 2009 September 60 (9):2666-76. Epub 1900 01 01.

Translational perspectives on psoriatic arthritis.

Ritchlin CT, Proulx S, Schwarz ES

The Journal of rheumatology. Supplement.. 2009 August 83 :30-4. Epub 1900 01 01.

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.

Mease PJ, Reich K,

Journal of the American Academy of Dermatology.. 2009 March 60 (3):402-11. Epub 11/25/2008.

An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform.

Wang JC, Kobie JJ, Zhang L, Cochran M, Mosmann TR, Ritchlin CT, Quataert SA

Journal of immunological methods.. 2009 February 28341 (1-2):106-16. Epub 12/03/2008.

The comparative effectiveness of methotrexate and anti-tumor necrosis factor therapy in psoriatic arthritis.

Ritchlin CT

Current rheumatology reports.. 2008 August 10 (4):295-6. Epub 1900 01 01.

Altered bone remodeling in psoriatic arthritis.

Mensah KA, Schwarz EM, Ritchlin CT

Current rheumatology reports.. 2008 August 10 (4):311-7. Epub 1900 01 01.

2007 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN).

Colbert RA, Deodhar AA, Khan MA, Lories RJ, Maksymowych WP, Reveille JD, Ritchlin CT, Rosenbaum JT, Targan SR, Weisman M, Clegg DO,

The Journal of rheumatology.. 2008 July 35 (7):1398-402. Epub 05/15/2008.

Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging.

Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, Calvi LM, Ritchlin CT, Awad HA, Boyce BF, Xing L, Schwarz EM

Arthritis and rheumatism.. 2008 July 58 (7):2019-29. Epub 1900 01 01.

From skin to bone: translational perspectives on psoriatic disease.

Ritchlin CT

The Journal of rheumatology.. 2008 July 35 (7):1434-7. Epub 1900 01 01.

Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review.

Coates LC, Anderson RR, Fitzgerald O, Gottlieb AB, Kelly SG, Lubrano E, McGonagle DG, Olivieri I, Ritchlin CT, Tan AL, De Vlam K, Helliwell PS

The Journal of rheumatology.. 2008 July 35 (7):1438-42. Epub 1900 01 01.

The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.

Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT

Annals of the rheumatic diseases.. 2008 March 67 (3):296-301. Epub 10/29/2007.

Psoriatic disease--from skin to bone.

Ritchlin C

Nature clinical practice. Rheumatology.. 2007 December 3 (12):698-706. Epub 1900 01 01.

Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography.

Proulx ST, Kwok E, You Z, Papuga MO, Beck CA, Shealy DJ, Ritchlin CT, Awad HA, Boyce BF, Xing L, Schwarz EM

Arthritis and rheumatism.. 2007 December 56 (12):4024-37. Epub 1900 01 01.

MRI and quantification of draining lymph node function in inflammatory arthritis.

Proulx ST, Kwok E, You Z, Beck CA, Shealy DJ, Ritchlin CT, Boyce BF, Xing L, Schwarz EM

Annals of the New York Academy of Sciences.. 2007 November 1117 :106-23. Epub 07/23/2007.

Consensus on a core set of domains for psoriatic arthritis.

Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J

The Journal of rheumatology.. 2007 May 34 (5):1167-70. Epub 1900 01 01.

Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.

Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP

The Journal of rheumatology.. 2007 March 34 (3):623-33. Epub 1900 01 01.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH

Arthritis and rheumatism.. 2007 February 56 (2):476-88. Epub 1900 01 01.

National Psoriasis Foundation clinical consensus on disease severity.

Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ,

Archives of dermatology.. 2007 February 143 (2):239-42. Epub 1900 01 01.

Clinical development of anti-RANKL therapy.

Schwarz EM, Ritchlin CT

Arthritis research & therapy.. 2007 9 Suppl 1 (Suppl 1):S7. Epub 1900 01 01.

Quality indicators in psoriatic arthritis.

Kavanaugh A, Ritchlin C, Boehncke WH

Clinical and experimental rheumatology.. 2007 25 (6 Suppl 47):98-101. Epub 1900 01 01.

Metabolic disorders in patients with psoriasis and psoriatic arthritis.

Mallbris L, Ritchlin CT, Ståhle M

Current rheumatology reports.. 2006 October 8 (5):355-63. Epub 1900 01 01.

MRI outcomes in AS patients after two years of etanercept therapy.

Ritchlin C, Maksymowych W

Current rheumatology reports.. 2006 August 8 (4):253-4. Epub 1900 01 01.

Therapies for psoriatic enthesopathy. A systematic review.

Ritchlin CT

The Journal of rheumatology.. 2006 July 33 (7):1435-8. Epub 05/15/2006.

Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.

Kavanaugh AF, Ritchlin CT,

The Journal of rheumatology.. 2006 July 33 (7):1417-21. Epub 05/15/2006.

Efficacy and safety of infliximab for the treatment of psoriatic arthritis.

Ritchlin C

Nature clinical practice. Rheumatology.. 2006 June 2 (6):300-1. Epub 1900 01 01.

Autoimmunity and bone.

Schwarz EM, Looney RJ, Drissi MH, O'Keefe RJ, Boyce BF, Xing L, Ritchlin CT

Annals of the New York Academy of Sciences.. 2006 April 1068 :275-83. Epub 1900 01 01.

Newer therapeutic approaches: spondyloarthritis and uveitis.

Ritchlin C

Rheumatic diseases clinics of North America.. 2006 February 32 (1):75-90, viii. Epub 1900 01 01.

A Medical Conundrum: Development of Psoriasis Following Anti-TNF Therapy

Tausk, F.; Ritchlin, C.T.

Annals of Rheumatic Diseases. 2006; 65(12): 1541-1544.

The efficacy and safety of adalimumab in psoriatic arthritis

Ritchlin, C.T.

Current Rheumatology Reports. 2006; 8(5): 329-331.

Psoriatic Arthritis: Making a Difficult Diagnosis.

Kleiner, A.; Ritchlin, C.T.

Journal of Musculoskeletal Medicine. 2006; : 1206-1218.

Clinical Trials Report

Ritchlin, C.T.; Maksymowych, W.

Current Rheumatology Reports. 2006; 8(4): 253-255.

Systematic Review of Treatments for Psoriatic Arthritis: Evidenced based Approach and Basis for Treatment Guidelines

Kavanaugh, A.; Ritchlin, C.T.; et al.

Journal of Rheumatology. 2006; 33(7): 1417-21.

Autoimmunity and bone

Schwarz, E.M.; Looney ,R.J.; Drissi, M.H.; O'Keefe, R.J.; Boyce, B.F.; Xing, L.; Ritchlin, C.T.

Annals of the New York Academy of Science. 2006; 1068: 275-283.

Outcome measures in psoriatic arthritis.

Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, Kavanaugh AF, Nash P, Ritchlin CT, Strand CV, Taylor W

The Journal of rheumatology.. 2005 November 32 (11):2262-9. Epub 1900 01 01.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA,

Arthritis and rheumatism.. 2005 October 52 (10):3279-89. Epub 1900 01 01.

Pathogenesis of psoriatic arthritis.

Ritchlin CT

Current opinion in rheumatology.. 2005 July 17 (4):406-12. Epub 1900 01 01.

Doxycycline in undifferentiated spondyloarthropathy.

Ritchlin CT

Current rheumatology reports.. 2005 June 7 (3):171-2; discussion 172. Epub 1900 01 01.

Treatment of reactive arthritis with azithromycin.

Ritchlin CT

Current rheumatology reports.. 2005 June 7 (3):171. Epub 1900 01 01.

Treatment update on spondyloarthropathy.

Anandarajah A, Ritchlin CT

Current opinion in rheumatology.. 2005 May 17 (3):247-56. Epub 1900 01 01.

Psoriatic arthritis clinical registries and genomics.

Gladman DD, Ritchlin C, Helliwell PS

Annals of the rheumatic diseases.. 2005 March 64 Suppl 2 (Suppl 2):ii103-5. Epub 1900 01 01.

Immunopathology of psoriasis and psoriatic arthritis.

Veale DJ, Ritchlin C, FitzGerald O

Annals of the rheumatic diseases.. 2005 March 64 Suppl 2 (Suppl 2):ii26-9. Epub 1900 01 01.

Discussion: Immunology, cellular pathology, genetic

Ritchlin, C.T.

Annals of Rheumatic Diseases. 2005; 64(Supplement II): ii40-ii41.

Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis.

Batliwalla FM, Li W, Ritchlin CT, Xiao X, Brenner M, Laragione T, Shao T, Durham R, Kemshetti S, Schwarz E, Coe R, Kern M, Baechler EC, Behrens TW, Gregersen PK, Gulko PS

Molecular medicine.. 2005 11 (1-12):21-9. Epub 1900 01 01.

Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents.

Anandarajah AP, Ritchlin CT

Postgraduate medicine.. 2004 November 116 (5):31-6, 39-40. Epub 1900 01 01.

RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.

Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ

Journal of musculoskeletal & neuronal interactions.. 2004 September 4 (3):276-84. Epub 1900 01 01.

Comparison of methotrexate and cyclosporine therapy in psoriasis.

Ritchlin CT

Current rheumatology reports.. 2004 August 6 (4):289, 291. Epub 1900 01 01.

Efalizumab therapy in plaque psoriasis.

Ritchlin CT

Current rheumatology reports.. 2004 August 6 (4):289-91. Epub 1900 01 01.

Treatment of psoriasis with intramuscular alefacept.

Ritchlin CT

Current rheumatology reports.. 2004 August 6 (4):290-1. Epub 1900 01 01.

Etanercept monotherapy in psoriasis.

Ritchlin CT

Current rheumatology reports.. 2004 August 6 (4):290-1. Epub 1900 01 01.

Pathogenesis of psoriatic arthritis.

Anandarajah AP, Ritchlin CT

Current opinion in rheumatology.. 2004 July 16 (4):338-43. Epub 1900 01 01.

Mechanisms of erosion in rheumatoid arthritis.

Ritchlin CT

The Journal of rheumatology.. 2004 July 31 (7):1229-37. Epub 1900 01 01.

Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.

Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB

The Journal of rheumatology.. 2004 July 31 (7):1356-61. Epub 1900 01 01.

Assessment of patients with psoriatic arthritis: a review of currently available measures.

Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W

Arthritis and rheumatism.. 2004 January 50 (1):24-35. Epub 1900 01 01.

Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.

Li P, Schwarz EM, O'Keefe RJ, Ma L, Looney RJ, Ritchlin CT, Boyce BF, Xing L

Arthritis and rheumatism.. 2004 January 50 (1):265-76. Epub 1900 01 01.

Clinical trials update: Anti-TNF agents in ankylosing spondylitis

Ritchlin, C.T.

Current Rheumatology Reports. 2004; 6(2): 95-97.

Section Editor, Seronegative Arthritis

Ritchlin, C.T.

Current Rheumatology Reports. 2004; 6(2): 95-125.

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM

The Journal of clinical investigation.. 2003 March 111 (6):821-31. Epub 1900 01 01.

Etanercept in psoriatic arthritis.

Anandarajah AP, Ritchlin CT

Expert opinion on biological therapy.. 2003 February 3 (1):169-77. Epub 1900 01 01.

Psoriatic Arthritis

Vaz, A.; Barton, J.; Ritchlin, C.T.

International Journal of Advances in Rheumatology. 2003; : 236-243.

Advances in the treatment of psoriatic arthritis: Effects of TNF inhibitors

Ritchlin, C.T.

Journal of Musculoskeletal Medicine. 2003; : S13-S20.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-alpha.

Ritchlin CT

Current rheumatology reports.. 2002 December 4 (6):497. Epub 1900 01 01.

Intravenous pamidronate in treatment of non-steroidal anti-inflammatory drug-refractory ankylosing spondylitis.

Ritchlin CT

Current rheumatology reports.. 2002 December 4 (6):498-9. Epub 1900 01 01.

Pseudoxanthoma elasticum masquerading as Sjögren's syndrome.

Daikh BE, Kalmar JJ, Ritchlin CT

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.. 2002 April 8 (2):89-93. Epub 1900 01 01.

New therapies in rheumatoid arthritis

Daikh, B.; Ritchlin, C.T.

Clinical Researcher. 2002; 2(8): 15-20.

Section Editor, Spondyloarthropathies

Ritchlin, C.T.

Current Rheumatology Reports. 2002; 4(6): 498-532.

Update on clinical trials for spondyloarthropathies

Ritchlin CT.

Current Rheumatology Reports. 2002; 4(6): 497.

Recent advances in the treatment of the seronegative spondyloarthropathies.

Ritchlin CT, Daikh BE

Current rheumatology reports.. 2001 October 3 (5):399-403. Epub 1900 01 01.

Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA

Archives of dermatology.. 2001 July 137 (7):893-9. Epub 1900 01 01.

Expression of interleukin 10 mRNA and protein by synovial fibroblastoid cells.

Ritchlin C, Haas-Smith SA

The Journal of rheumatology.. 2001 April 28 (4):698-705. Epub 1900 01 01.

Section Editor, Spondyloarthropathies

Ritchlin, C.T.

Current Rheumatology Reports. 2001; 3(5): 399-404.

The pathogenesis of psoriatic arthritis

Ritchlin, C.

Journal of Musculoskeletal Medicine. 2001; 18(5): S37-S44.

The synovial fibroblast as an effector cell in inflammatory arthritis

Ritchlin, C.

Arthritis Research and Therapy. 2000; 2: 356-360.

Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis.

Ritchlin C

Arthritis research.. 2000 2 (5):356-60. Epub 06/23/2000.

Patterns of cytokine production in psoriatic synovium.

Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ

The Journal of rheumatology.. 1998 August 25 (8):1544-52. Epub 1900 01 01.

Alternative pathways of inflammation in rheumatoid arthritis

Ritchlin, C.

Clinical Immunology Newsletter. 1996; 16(4): 57-62.

Collagenase and stromelysin expression in rheumatoid synovium and cartilage: comment on the article by Wolfe et al.

Ritchlin C, Haas-Smith S

Arthritis and rheumatism.. 1994 December 37 (12):1831-3. Epub 1900 01 01.

Olsalazine in Reiter's syndrome.

Zwillich SH, Ritchlin CT

The Journal of rheumatology.. 1994 November 21 (11):2169-70. Epub 1900 01 01.

Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis.

Ritchlin C, Dwyer E, Bucala R, Winchester R

Scandinavian journal of immunology.. 1994 September 40 (3):292-8. Epub 1900 01 01.

Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation.

Hogan M, Sherry B, Ritchlin C, Fabre M, Winchester R, Cerami A, Bucala R

Cytokine.. 1994 January 6 (1):61-9. Epub 1900 01 01.

Tissue distribution and inflammatory regulation of synovial collagenase

Rose, S.; Konttinen, Y.; Sorsa, T.; Lindy, O.; Saari, H.; Choi, S.; Törnwall, J.; Teronen, O.; Ritchlin, C.

Progress in Rheumatology. 1993; 1: 21-25.

Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus.

Ritchlin CT, Chabot RJ, Alper K, Buyon J, Belmont HM, Roubey R, Abramson SB

Arthritis and rheumatism.. 1992 November 35 (11):1330-42. Epub 1900 01 01.

Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia.

Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, Christian CL

The Journal of rheumatology.. 1992 August 19 (8):1191-4. Epub 1900 01 01.

Collagenase in synovitis of rheumatoid arthritis.

Sorsa T, Konttinen YT, Lindy O, Ritchlin C, Saari H, Suomalainen K, Eklund KK, Santavirta S

Seminars in arthritis and rheumatism.. 1992 August 22 (1):44-53. Epub 1900 01 01.

Substrate specificity and activation mechanisms of collagenase from human rheumatoid synovium.

Konttinen YT, Lindy O, Suomalainen K, Ritchlin C, Saari H, Vauhkonen M, Lauhio A, Santavirta S, Sorsa T

Matrix (Stuttgart, Germany). 1991 December 11 (6):395-403. Epub 1900 01 01.

Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts.

Bucala R, Ritchlin C, Winchester R, Cerami A

The Journal of experimental medicine.. 1991 March 1173 (3):569-74. Epub 1900 01 01.

Potential mechanisms for coordinate gene activation in the rheumatoid synoviocyte: implications and hypotheses.

Ritchlin CT, Winchester RJ

Springer seminars in immunopathology.. 1989 11 (3):219-34. Epub 1900 01 01.

Treatment recommendations in psoriatic arthritis.

Ritchlin, C.T.; Kavanaugh, A.; Gladman, D.D.; et al.

What's new in psoriasis?

Ritchlin, C.T.

Rheumatology in Practice. .

Centers for Psoriatic Disease

Ritchlin, C.T.; Tausk, F.

Current Opinion in Rheumatology. .

Altered bone remodeling in psoriatic arthritis

Mensah, K.; Schwarz, E.; Ritchlin, C.T.

Current Rheumatology Reports. .

Elucidating bone marrow edema in murine arthritis using contrast enhanced MRI

Proulx, S.; Kwok, E.; You, Z.; Papuga, M.O.; Bexk, C..; Shealy, D.J.; Calvi, L.; Ritchlin, C.T.; Awad, H.; Boyce, B.; Xing, L.; Schwarz, E.

Arthritis and Rheumatism. .

Books

Pathogenesis of Psoriatic Arthritis (2010)

Authors: Ritchlin, CT, McGonagle, DA

Publisher: Elsevier, Philadelphia 2010

Psoriatic and Reactive Arthritis (2007)

Chapter: Pathogenesis of Psoriatic Arthritis

Authors: Ritchlin CT, Fitzgerald O.

Publisher: Elsevier, Philadelphia 2007

Primer of Rheumatic Diseases (2007)

Chapter: Epidemiology and Pathogenesis of Psoriatic Arthritis

Authors: Ritchlin, C.T.

Publisher: Arthritis Foundation, Atlanta 2007

Rheumatology (2007)

Chapter: Treatment of Psoriatic Arthritis

Authors: Ritchlin, C.T.

Publisher: Elsevier, Philadelphia 2007

Atlas of Psoriatic Arthritis (2006)

Chapter: Pathogenesis of Psoriatic Arthritis

Authors: Barton, J. and Ritchlin, C.T.

Publisher: Science Press Ltd, London 2006

Psoriasis and Psoriatic Arthritis: An Integrated Approach (2004)

Chapter: Pathogenesis of Psoriatic Arthritis

Authors: Barton, J. and Ritchlin, C.T.

Publisher: Springer-Verlag, Newark 2004

Primary Care of Women (2003)

Chapter: Systemic Lupus Erythematosus

Authors: Ritchlin, C.

Publisher: J.B. Lippincott, Philadelphia 2003

Primer on Rheumatic Diseases (1998)

Chapter: Reflex Sympathetic Dystrophy and Regional Transient Osteoporosis

Authors: Ritchlin, C.T.

Publisher: Arthritis Foundation, Atlanta 1998

Primer on Rheumatic Diseases (1997)

Chapter: Reflex Sympathetic Dystrophy and Regional Transient Osteoporosis

Authors: Ritchlin, C.T.

Publisher: Arthritis Foundation, Atlanta 1997

Primary Care of Women (1997)

Chapter: Systemic Lupus Erythematosus

Authors: Ritchlin, C.T.

Publisher: J.B. Lippincott, Philadelphia 1997

Primary Care of Women (1997)

Chapter: Evaluation of the Patient with Musculoskeletal Symptoms

Authors: Ritchlin, C.T.

Publisher: J.B. Lippincott, Philadelphia 1997

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

During this visit, did this provider spend enough time with you?

4.8 stars

During this visit, did this provider show respect for what you had to say?

4.9 stars

During this visit did this provider give you easy to understand information about these health questions or concerns?

4.8 stars

During this visit, did this provider listen carefully to you?

4.8 stars

During this visit, did this provider explain things in a way that was easy to understand?

4.8 stars

Patient Comments

5.0 stars

Was great evaluating me.

Jan 04, 2024

5.0 stars

Dr. and his team are excellent! Thorough, caring and prompt response through MyChart.

Mar 08, 2023

5.0 stars

I like Dr. Ritchlin [...]

Jun 03, 2022